{"id":"ropinirole","brandName":"Requip","genericName":"ropinirole","companyId":"gsk","companyName":"GSK","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":1,"mechanism":{"target":"D(1B) dopamine receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A"},"administration":{"route":"Oral"},"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"1369 reports"},{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"1196 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1146 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"1085 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"864 reports"},{"date":"","signal":"HALLUCINATION","source":"FDA FAERS","actionTaken":"846 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"769 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"750 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"736 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"717 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Nausea","drugRate":"60%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"40%","severity":"common","organSystem":""},{"effect":"Asthenic condition","drugRate":"16%","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"10%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"12%","severity":"common","organSystem":""},{"effect":"Leg edema","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Pain","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Increased sweating","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Dry mouth","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Dependent edema","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Chest pain","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Anorexia","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Flatulence","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Hypertension","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Hypotension","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Flushing","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Hyperkinesia","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Hypesthesia","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Vertigo","drugRate":"2%","severity":"common","organSystem":""}],"contraindications":["Acute nephropathy","Bradycardia","Central nervous system depression","Drowsy","Dyskinesia","Hallucinations","Hepatic failure","Low blood pressure","Orthostatic hypotension","Psychotic disorder","Smokes tobacco daily","Syncope"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Syncope","drugRate":"12%","severity":"serious"},{"effect":"Hallucinations/psychotic-like behavior","drugRate":"","severity":"serious"},{"effect":"Withdrawal-emergent hyperpyrexia and confusion","drugRate":"","severity":"serious"},{"effect":"Fibrotic complications","drugRate":"","severity":"serious"},{"effect":"Retinal pathology","drugRate":"","severity":"serious"},{"effect":"Orthostatic hypotension","drugRate":"6%","severity":"serious"},{"effect":"Dyskinesia","drugRate":"","severity":"serious"},{"effect":"Impulse control/compulsive behaviors","drugRate":"","severity":"serious"},{"effect":"Augmentation and early-morning rebound in RLS","drugRate":"","severity":"serious"},{"effect":"Falling asleep during activities of daily living","drugRate":"","severity":"serious"}]},"trials":["NCT00367822","NCT00399477","NCT00460148","NCT00314860","NCT02994719","NCT01435915","NCT01154166","NCT00639119","NCT00363857","NCT00419692","NCT00530790","NCT00355641","NCT00260793","NCT00373542","NCT00282152","NCT01515774","NCT00275275","NCT01007864","NCT00996944","NCT01976871","NCT00331149","NCT00140712","NCT01723904","NCT00823836","NCT00344994","NCT01627847","NCT00334048","NCT00593606","NCT01627834","NCT00485069","NCT00256854","NCT01628926","NCT00465452","NCT00314821","NCT01712568","NCT00305331","NCT00243971","NCT03038308","NCT00422994","NCT01714856","NCT00144300","NCT01929317","NCT01371682","NCT00605683","NCT00329602","NCT00036218","NCT00285727","NCT00256893","NCT00830219","NCT00650104"],"indications":{"approved":[{"name":"Parkinson's disease","diseaseId":"parkinson's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Restless legs","diseaseId":"restless-legs","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT00367822","phase":"Phase 3","title":"Transdermal Lisuride: a Double-blind, Randomized, Active- and Placebo-controlled Multi-centre Phase III Efficacy Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)","status":"COMPLETED","sponsor":"Axxonis Pharma AG","isPivotal":true,"enrollment":300,"indication":"Restless Legs Syndrome","completionDate":""},{"nctId":"NCT00399477","phase":"Phase 4","title":"Open-label, Multicenter, Effectiveness and Safety Study of Once Daily AZILECT® as Mono- or Adjunct Therapy in Patients With Idiopathic Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"Teva Neuroscience, Inc.","isPivotal":false,"enrollment":200,"indication":"Parkinson's Disease","completionDate":"2007-07"},{"nctId":"NCT00460148","phase":"Phase 2","title":"An Open Label, Repeat Dose, Dose Escalation Study Conducted in Parkinson's Disease Patients to Characterize the Pharmacokinetics and Effect of Food on Ropinirole Prolonged Release (PR/CR) 12mg Tablets","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":28,"indication":"Parkinson Disease","completionDate":"2007-08"},{"nctId":"NCT00314860","phase":"Phase 3","title":"A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate R","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":568,"indication":"Restless Legs Syndrome, Restless Legs Syndrome (RLS)","completionDate":"2006-12"},{"nctId":"NCT02994719","phase":"N/A","title":"Gait Pattern Analysis in Neurological Disease","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","isPivotal":false,"enrollment":120,"indication":"Parkinson's Disease, Parkinsonian Disorders","completionDate":"2026-06-20"},{"nctId":"NCT01435915","phase":"Phase 1","title":"A Single Dose and Repeat Dose Study to Investigate the Pharmacokinetics of Ropinirole After Single and Multiple Doses of a PR-formulation in Chinese Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":24,"indication":"Parkinson Disease","completionDate":"2010-08-05"},{"nctId":"NCT01154166","phase":"Phase 3","title":"A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optima","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":347,"indication":"Parkinson Disease","completionDate":"2011-09-29"},{"nctId":"NCT00639119","phase":"Phase 2","title":"Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type","status":"UNKNOWN","sponsor":"University of Turku","isPivotal":false,"enrollment":16,"indication":"Unverricht-Lundborg Syndrome","completionDate":""},{"nctId":"NCT00363857","phase":"Phase 3","title":"A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering From Restless Legs Syndrome (RLS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":360,"indication":"Restless Legs Syndrome (RLS), Restless Legs Syndrome","completionDate":"2004-05"},{"nctId":"NCT00419692","phase":"Phase 1","title":"An Open Label, Repeat Dose, Dose Escalation Study Conducted in RLS Patients to Characterize Pharmacokinetics and Food Effect of Ropinirole Controlled Release for RLS","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":32,"indication":"Restless Legs Syndrome","completionDate":"2006-12-12"},{"nctId":"NCT00530790","phase":"Phase 2","title":"Clinical Evaluation of Ropinirole CR-RLS Tablets in Restless Legs Syndrome-Open-Label, Uncontrolled Study. Classification: Clinical Pharmacology, Exploratory","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":35,"indication":"Restless Legs Syndrome","completionDate":"2008-02-01"},{"nctId":"NCT00355641","phase":"Phase 3","title":"A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients With Restless Legs Syndrome (RLS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":450,"indication":"Restless Legs Syndrome","completionDate":"2007-10"},{"nctId":"NCT00260793","phase":"Phase 3","title":"Open Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinson's Disease","status":"UNKNOWN","sponsor":"Agarwal, Pinky, M.D.","isPivotal":true,"enrollment":20,"indication":"Parkinson's Disease","completionDate":""},{"nctId":"NCT00373542","phase":"Phase 4","title":"A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients With Sl","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":39,"indication":"Restless Legs Syndrome (RLS), Restless Legs Syndrome","completionDate":"2007-06"},{"nctId":"NCT00282152","phase":"NA","title":"Safety and Tolerability of Neurostimulation in Early Stage Parkinson's Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","isPivotal":false,"enrollment":37,"indication":"Parkinson's Disease","completionDate":"2015-10"},{"nctId":"NCT01515774","phase":"Phase 4","title":"An Open-label, Randomized, Multi-center, Crossover Study to Observe the Effect of Once-daily Mirapex ER® and Twice-daily Mirapex ER® in Patients With Parkinson Disease","status":"UNKNOWN","sponsor":"Seoul National University Hospital","isPivotal":false,"enrollment":200,"indication":"Parkinson's Disease","completionDate":"2012-10"},{"nctId":"NCT00275275","phase":"Phase 3","title":"An Open Label Conversion Study of Pramipexole to Ropinirole Controlled Release (CR) in Patients With Parkinson's Disease.","status":"COMPLETED","sponsor":"Rajesh Pahwa, MD","isPivotal":true,"enrollment":61,"indication":"Parkinson Disease","completionDate":"2008-05"},{"nctId":"NCT01007864","phase":"Phase 3","title":"Influence of the Non-Ergot Dopamine Agonist Piribedil on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Oral Non-Ergot Dopamine Agonists","status":"COMPLETED","sponsor":"Desitin Arzneimittel GmbH","isPivotal":true,"enrollment":80,"indication":"Idiopathic Parkinson's Disease","completionDate":"2011-12"},{"nctId":"NCT00996944","phase":"Phase 2","title":"Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With H","status":"TERMINATED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":34,"indication":"Restless Legs Syndrome","completionDate":"2010-06-29"},{"nctId":"NCT01976871","phase":"Phase 4","title":"A Method to Switch From Oral Dopamine Agonists to Rotigotine in Patients With Restless Legs Syndrome","status":"COMPLETED","sponsor":"John Winkelman, MD, PhD","isPivotal":false,"enrollment":21,"indication":"Restless Legs Syndrome, Ekbom Syndrome","completionDate":"2015-12"},{"nctId":"NCT00331149","phase":"Phase 3","title":"A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment With Ropinirole Immediate Release Tablets (REQUIP IR) or Ropinirole Prolonged Release Tablets (SK&F-101468)","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":343,"indication":"Parkinson Disease","completionDate":"2007-08-29"},{"nctId":"NCT00140712","phase":"Phase 1","title":"A Study to Determine the Tolerability and Pharmacokinetics for Ropinirole in Paediatric / Adolescent Patients With RLS (Type 2)","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":9,"indication":"Restless Legs Syndrome","completionDate":"2008-02-28"},{"nctId":"NCT01723904","phase":"Phase 3","title":"An Open-Label Study to Investigate the Safety and Efficacy of Rotigotine Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3B","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","isPivotal":true,"enrollment":90,"indication":"Advanced Parkinson's Disease","completionDate":"2013-04"},{"nctId":"NCT00823836","phase":"Phase 3","title":"Clinical Evaluation of Ropinirole PR/XR Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":302,"indication":"Parkinson Disease","completionDate":"2010-12"},{"nctId":"NCT00344994","phase":"Phase 4","title":"An Open-Label Prospective Study of Restless Legs Patients Switched to Ropinirole From Pramipexole to Help Determine the Equipotent Dose","status":"COMPLETED","sponsor":"Augusta University","isPivotal":false,"enrollment":20,"indication":"Restless Legs Syndrome","completionDate":"2010-04"},{"nctId":"NCT01627847","phase":"Phase 1","title":"Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Oral Bioequivalence Study of Ropinirole Hydrochloride Extended Release Tablets 2 mg of Dr. Reddy's Lab","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","isPivotal":false,"enrollment":48,"indication":"Healthy","completionDate":"2009-11"},{"nctId":"NCT00334048","phase":"Phase 4","title":"Treatment of Sexual Dysfunction Secondary to Antidepressant Pharmacotherapy: A Double-blind Comparison of Requip (Ropinirole) vs. Placebo in Patients Taking SSRI Antidepressants","status":"COMPLETED","sponsor":"St. Luke's-Roosevelt Hospital Center","isPivotal":false,"enrollment":9,"indication":"Sexual Dysfunction","completionDate":"2007-09"},{"nctId":"NCT00593606","phase":"Phase 3","title":"A Phase 3b, Open-Label, Multicenter Trial to Assess the Safety and Tolerability of Switching Korean Subjects From Ropinirole to the Rotigotine Transdermal System and Its Effect on Symptoms in Idiopath","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":true,"enrollment":124,"indication":"Parkinson's Disease","completionDate":"2007-12"},{"nctId":"NCT01627834","phase":"Phase 1","title":"Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Oral Bioequivalence Study of Ropinirole Hydrochloride Extended Release Tablets 2 mg of Dr. Reddy's Lab","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","isPivotal":false,"enrollment":48,"indication":"Healthy","completionDate":"2009-11"},{"nctId":"NCT00485069","phase":"Phase 4","title":"Post-Marketing Clinical Study of REQUIP (Ropinirole Hydrochloride) Tablets in Patients With Parkinson's Disease- Evaluation of Long-Term Efficacy and Safety -","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":123,"indication":"Parkinson Disease, Parkinson's Disease","completionDate":"2009-12"},{"nctId":"NCT00256854","phase":"Phase 3","title":"A 4-Week, Randomized, Double-Blind, Cohort Study to Evaluate the Safety and Tolerability of Converting From Ropinirole Immediate Release (IR) to Ropinirole Controlled Release for RLS (CR-RLS) Formulat","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":135,"indication":"Restless Legs Syndrome, Restless Legs Syndrome (RLS)","completionDate":"2006-09-21"},{"nctId":"NCT01628926","phase":"Phase 3","title":"A Double-Blind, 3-Arm, Parallel Group, Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","isPivotal":true,"enrollment":420,"indication":"Parkinson's Disease","completionDate":"2011-05"},{"nctId":"NCT00465452","phase":"Phase 3","title":"The Impact of Switching to Continuous Release Dopamine Agonists on Non-Motor Side Effects","status":"COMPLETED","sponsor":"University of Toledo","isPivotal":true,"enrollment":11,"indication":"Parkinson Disease","completionDate":"2011-12"},{"nctId":"NCT00314821","phase":"Phase 4","title":"A Randomized, Double-blind, Placebo-controlled Study of the Efficacy of Ropinirole in the Treatment of Depression in Bipolar Disorder","status":"COMPLETED","sponsor":"Cambridge Health Alliance","isPivotal":false,"enrollment":40,"indication":"Bipolar Disorder","completionDate":"2008-03-17"},{"nctId":"NCT01712568","phase":"Phase 1","title":"AN OPEN LABEL, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, BIOEQUIVALENCE STUDY OF ROPINIROLE HYDROCHLORIDE CR 2mg TABLETS OF LUPIN LIMITED, INDIA, COMPARING WITH THAT OF REQUIP XL","status":"COMPLETED","sponsor":"Lupin Ltd.","isPivotal":false,"enrollment":12,"indication":"Pharmacokinetic Study","completionDate":"2008-10"},{"nctId":"NCT00305331","phase":"Phase 2","title":"Phase II Clinical Trial of Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease","status":"TERMINATED","sponsor":"University Health Network, Toronto","isPivotal":false,"enrollment":25,"indication":"Parkinson's Disease, Peripheral Edema","completionDate":"2008-09"},{"nctId":"NCT00243971","phase":"Phase 3","title":"A Phase 3, Randomized, Open-Label, Two-Arm, Parallel-Group, Multicenter, Multinational Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impair","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":true,"enrollment":0,"indication":"Parkinson's Disease","completionDate":"2005-10"},{"nctId":"NCT03038308","phase":"Phase 1","title":"Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability","status":"COMPLETED","sponsor":"Columbia University","isPivotal":false,"enrollment":16,"indication":"Hyperprolactinemia, Prolactinoma","completionDate":"2020-11-05"},{"nctId":"NCT00422994","phase":"Phase 1","title":"An Open-Label, Parallel-Group, Repeat-Dose Study to Investigate the Effects of End Stage Renal Disease and Haemodialysis on the Pharmacokinetics of Ropinirole (Study RRL103628)","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":48,"indication":"Restless Legs Syndrome","completionDate":"2006-12"},{"nctId":"NCT01714856","phase":"Phase 1","title":"AN OPEN LABEL, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, BIOEQUIVALENCE STUDY OF ROPINIROLE HYDROCHLORIDE CR 2mg TABLETS OF LUPIN LIMITED, INDIA, COMPARING WITH THAT OF REQUIP XL","status":"COMPLETED","sponsor":"Lupin Ltd.","isPivotal":false,"enrollment":12,"indication":"Pharmacokinetic Study","completionDate":"2008-11"},{"nctId":"NCT00144300","phase":"Phase 4","title":"A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":246,"indication":"Parkinson Disease","completionDate":""},{"nctId":"NCT01929317","phase":"Phase 3","title":"A Study ROP116991, Clinical Evaluation of 18 to 24mg/Day Ropinirole CR for Parkinson's Disease.","status":"TERMINATED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":81,"indication":"Parkinson Disease","completionDate":"2015-06-09"},{"nctId":"NCT01371682","phase":"Phase 1","title":"An Open Label Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets (Ropinirole XL, Marketed as REQUIP-MODUTAB™, REQUIP XL™ at 2 mg) Manufactur","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":50,"indication":"Parkinson Disease","completionDate":"2009-12-02"},{"nctId":"NCT00605683","phase":"Phase 3","title":"A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With E","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","isPivotal":true,"enrollment":679,"indication":"Idiopathic Parkinson's Disease","completionDate":"2012-03"},{"nctId":"NCT00329602","phase":"Phase 4","title":"A Parallel Group Study to Evaluate the Efficacy and Safety of Ropinirole for 26 Weeks and to Further Evaluate the Incidence of Augmentation and Rebound for a Further 40 Weeks Open-label Extension Trea","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":404,"indication":"Restless Legs Syndrome","completionDate":"2008-09"},{"nctId":"NCT00036218","phase":"Phase 3","title":"A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients With Early Parkinson's Disease.","status":"COMPLETED","sponsor":"Pfizer","isPivotal":true,"enrollment":600,"indication":"Parkinson Disease","completionDate":"2003-04"},{"nctId":"NCT00285727","phase":"NA","title":"Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression","status":"COMPLETED","sponsor":"Stanford University","isPivotal":false,"enrollment":60,"indication":"Depressive Disorder, Major","completionDate":"2007-10"},{"nctId":"NCT00256893","phase":"Phase 2","title":"A Randomised, Double Blind, Placebo-controlled, Parallel Group Study to Investigate the Safety and Efficacy of Controlled-release Ropinirole (CR) (1-24 mg) Administered Once Daily for 12 Weeks in Subj","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":164,"indication":"Fibromyalgia Syndrome, Primary","completionDate":"2005-07"},{"nctId":"NCT00830219","phase":"Phase 1","title":"The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","isPivotal":false,"enrollment":46,"indication":"Healthy","completionDate":"2004-11"},{"nctId":"NCT00650104","phase":"Phase 3","title":"101648/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients With Parkinson's Disease Who Completed the Previous Ropinirole CR Studies 167 o","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":76,"indication":"Parkinson Disease","completionDate":"2009-03"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0486/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$18","description":"ROPINIROLE HCL 0.25 MG TABLET","retrievedDate":"2026-04-07"}],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2011-10-31T00:00:00.000Z","mah":"ALEMBIC LTD","brand_name_local":null,"application_number":"ANDA090429"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-12-11T00:00:00.000Z","mah":"PRINSTON INC","brand_name_local":null,"application_number":"ANDA078110"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-01-10T00:00:00.000Z","mah":"ALEMBIC","brand_name_local":null,"application_number":"ANDA202786"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-10-27T00:00:00.000Z","mah":"GLENMARK PHARMS LTD","brand_name_local":null,"application_number":"ANDA090135"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-10-28T00:00:00.000Z","mah":"MLV","brand_name_local":null,"application_number":"ANDA079165"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ropinirole","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:18:50.522583+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:18:56.999344+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:18:49.646773+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ropinirole","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:18:57.350558+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:18:46.747044+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:18:46.747069+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:18:58.846926+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: D2-like dopamine receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:18:58.413133+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200411/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:18:58.062147+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA090429","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:18:46.747072+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:19:01.983263+00:00","fieldsConflicting":0,"overallConfidence":0.95},"crossReferences":{"chemblId":"CHEMBL1200411"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}